Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Lymphoma, also known as malignant lymphoma, is a general term for a group of malignant tumors originating from the lymphopoietic system. It is one of the most common tumors in China. In 2020, there were 544,352 new cases of non-Hodgkin lymphoma (NHL) worldwide, ranking 13th among all new cases of malignancies.

A November 2018 FDA inspection has resulted in a warning letter for Zeller Power Products. The Wallace, ID-based company makes a replacement battery for Cardiac Science's PowerHeart Automated External Defibrillator (AED) G3.

Robotics in medtech are quickly becoming common place as the number of companies in the market continue to grow. On June 12, seasoned veterans of robotic surgery companies will share their thoughts about the state of surgical robotics techno

Grail has hit a major milestone as the liquid biopsy company is reporting it has been granted Break Through Device Designation by FDA. The Menlo Park, CA-based company is developing an investigational next-generation sequencing (NGS) blood t

Illumina and the Childrens Hospital of Fudan University in China plan to launch a study of whole-genome sequencing in the hospitals neonatal intensive care unit to determine whether it can be used as a diagnostic for critically ill infants,

To understand the impact of genomic structural variation on human disease, GrandOmics, a leading domestic sequencing company, announced a large-scale sequencing project called dbSV-100K.The project aims to use high-throughput nanopore sequen

Recently, Kehua Biotech released the first quarter report of 2019. During the reporting period, the company realized the main business income of 506 million yuan, an increase of 11.8%; the net profit attributable to shareholders of listed co

Australian diagnostics firm Genetic Technologies said recently that it has signed a memorandum of understanding to commercialize its range of polygenic risk tests in the US with the Translational Genomics Research Institute. Under the terms

Thermo Fisher Scientific and NX Prenatal said recently that they have partnered on the development of mass spectrometry-based proteomics assays for adverse pregnancy outcomes. Under the terms of the deal, the companies will combine NXs NeXos

UK molecular diagnostics firm Yourgene Health said recently that it has agreed to acquire Elucigene for 9.2 million ($12.0 million) in cash and stock in a bid to bolster its presence in the noninvasive prenatal testing (NIPT) market. To fund

Natera announced recently that it has prices its $100 million common stock offering. The San Carlos, California-based molecular diagnostics firm is offering 5,263,158 shares of common stock at $19 per share. Gross proceeds from the offering